LOS ANGELES, CA, Jul 15, 2010 (MARKETWIRE via COMTEX News Network) -- According to a newly published report, Northwest Biotherapeutics' (OTCBB: NWBO) DCVax(R) may be poised to surpass Dendreon's product in the field of vaccine based cancer treatments. Speculators have begun to rush back to pick up shares of NWBO just as sector darling Dendreon Corporation has seen its shares lose 44% of their value after news that Dendreon can only make enough of their recently approved prostate cancer...
Full Story: Stockhouse
